Principal Investigator shares thoughts on TrueBinding Alzheimer's trial - Accel Research Sites

Create a Profile

I accept digital forms of communication(Required)
Hidden
Hidden
This field is for validation purposes and should be left unchanged.
Create a Profile
I accept digital forms of communication(Required)
Hidden
Hidden
This field is for validation purposes and should be left unchanged.

Get In Touch Mobile

I accept digital forms of communication(Required)
This field is for validation purposes and should be left unchanged.

FIND A TRIAL NEAR YOU

No location found for this Zip Code

-- or --

No location found for this Location

FIND A TRIAL NEAR YOU

No location found for this Zip Code

-- or --

No location found for this Location
Back
Date Published: 12/07/2022

Principal Investigator shares thoughts on TrueBinding Alzheimer’s trial

TrueBinding recently released results of a Phase 1b/2 trial for TB006, which showed improvements for patients with mild to severe Alzheimer’s Disease.

One of our valued primary investigators, Dr. Marshall Nash, participated in the trial and provided his feedback for the company’s findings release.  Accel is very proud to be part of these results, and we look forward to working with TrueBinding to see what comes next for TB006.

See the news here.

 

Read complete TrueBinding-Topline-Release

Back

Ready to be part of healthcare history? Find the right clinical trial for you.

Get In Touch

I accept digital forms of communication(Required)
This field is for validation purposes and should be left unchanged.
Accessibility Adjustment

Color Adjustment

Orientation Adjustment

Font Size

 

Line height